Telehealth-supported ketamine for depression and anxiety: A systematic review.
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists June 11, 2026 Eden Mane, Saras Mane
A systematic review of telehealth-supported ketamine for depression and anxiety in adults found that, across three US commercial provider studies, symptom response rates ranged from 49.5% to 62.8% on the PHQ-9 and 47.6% to 62.9% on the GAD-7, with remission rates of 20.7% to 32.6% and 23.9% to 31.3%, respectively. However, all studies were at critical risk of bias, the evidence certainty was very low, and follow-up data were available for only a minority of the up to 16,876 patients. The review concludes that the evidence is provider-generated and insufficient to guide clinical practice, though it may inform future hybrid service design in Australasia.